【 𝐃𝐉 𝐌𝐈𝐀 𝐋𝐚𝐝𝐢𝐞𝐬 𝐍𝐢𝐠𝐡𝐭 𝐓𝐚𝐤𝐞𝐨𝐯𝐞𝐫 】

Ranked among 𝐌𝐚𝐥𝐚𝐲𝐬𝐢𝐚’𝐬 𝐓𝐨𝐩 𝟏𝟎 𝐃𝐉𝐬, the iconic 𝐃𝐉 𝐌𝐈𝐀 is 𝐧𝐨𝐭 𝐟𝐨𝐮𝐧𝐝 in KL this week — she’s lighting up the decks only at 𝐌𝐢𝐝𝐧𝐢𝐠𝐡𝐭 𝐁𝐥𝐚𝐜𝐤.

This 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆 𝟐𝟓 𝐉𝐔𝐍𝐄 , No detours. No distractions. Just one city, one club, one night to lose control. 🙌🏻

💃🏼 Round up your girls, a group of 𝟰 𝗹𝗮𝗱𝗶𝗲𝘀 gets a 𝗙𝗥𝗘𝗘 𝗯𝗼𝘁𝘁𝗹𝗲 𝗼𝗳 𝗛𝗮𝗹𝗳 𝗠𝗼𝗼𝗻.

For table reservations or more info, contact us now:
https://midnightblackpg.com
🗓 http://wa.me/601116688825
Midnight Black Nightclub
130, Penang Road, George Town, Penang.
Daily 8pm - 3am

#midnightblackpg #yourfutureishere

The daily drawing that i did today

In June 2025, the U.S. Food and Drug Administration (FDA) officially approved Yeztugo (lenacapavir) as the world’s first twice-yearly injection for HIV prevention (PrEP).

Developed by Gilead Sciences, this landmark drug offers long-term protection from HIV with just two subcutaneous shots per year.

The approval is based on extensive clinical trials under the PURPOSE 1 and 2 studies, which showed near-perfect efficacy—zero new infections in cisgender women and only two infections across a broader population of over 2,000 individuals.

This brings its protective rate to approximately 99.9%, making it the most effective and long-acting HIV prevention method available today.

Lenacapavir works by targeting the HIV capsid, a protein shell that encases the virus’s genetic material.

By inhibiting this capsid, the drug prevents HIV from replicating inside human cells.

Unlike daily oral PrEP options like Truvada or Descovy, Yeztugo is designed to overcome common adherence issues by requiring just one injection every six months. This simplifies prevention for at-risk

populations, especially those who struggle with daily medication routines.

While the approval is being hailed as a major victory in the global fight against HIV, access and affordability remain concerns.

The U.S. list price for a year’s supply is expected to be around $28,000, though Gilead has committed to providing generics to 120 low-income countries and producing up to 10 million doses by 2026.

Global health experts see this breakthrough as a turning point that could drastically reduce new HIV infections—if distribution is equitable and timely.

In summary, Yeztugo's approval represents a critical milestone in HIV prevention science, combining exceptional efficacy, convenience, and innovation.

It has the potential to reshape the future of HIV prevention—especially if healthcare systems can ensure widespread access to those most in need.

Daily Nichijou meme #2622

China is redefining patient care with the launch of a smart hospital run by AI.
Developed by Tsinghua University, this next-gen facility can simulate treatments for 10,000 patients daily, using AI doctors that diagnose, prescribe, and even provide mental health support—all with real-time global learning.

These AI systems never get tired, don’t make clerical mistakes, and adapt faster than any human staff. While still in the testbed phase, it’s a bold leap toward a future where medicine is powered by machine intelligence.

Could this be a glimpse into the hospital of tomorrow?
Full breakdown:

#AIHealthcare #SmartHospital #FutureOfMedicine #ArtificialIntelligence #ChinaInnovation